anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Apply to affected area 3 to 4 times daily. Use the applicator supplied for anal administration. For perianal use, transfer a small quantity to a tissue and rub in gently.

Directions for Use.

1.
    Place cap on top of container. Shake foam container vigorously for 5-10 seconds before each use. Do not remove container cap during use of the product.
2.
    Hold container upright on a level surface and gently place the tip of the applicator onto the nose of the container cap. CONTAINER MUST BE HELD UPRIGHT TO OBTAIN PROPER FLOW OF MEDICATION.
3.
    Pull plunger past the fill line on the applicator barrel.
4.
    Hold the container and applicator at eye level. Place the index and middle fingers on the container cap flanges and the thumb beneath the container. Support the applicator with your other hand. Prime the container by pressing down firmly on flanges and then release. With initial priming, a burst of air may come out of the container. It usually requires 1-2 pumps for foam to appear.
5.
    To fill applicator barrel, press down firmly on cap flanges, hold for 1-2 seconds, and release. Wait 5-10 seconds to allow foam to expand in applicator barrel. Repeat until foam reaches fill line. It usually requires 3-4 pumps for foam to reach fill line. Remove applicator from container cap. Note: If foam goes beyond fill line, it will continue to expand and flow backwards resulting in foam build-up under cap.
6.
    Hold applicator firmly by barrel, making sure thumb and middle finger are positioned securely underneath and resting against barrel wings. Place index finger over the plunger. Gently insert tip into anus. Once in place, push plunger to expel foam, then withdraw applicator. CAUTION: Do not insert any part of the aerosol container directly into the anus. Apply to anus only with enclosed applicator. Do not insert any part of the applicator past the anus into rectum.
7.
    After each use, applicator parts should be pulled apart for thorough cleaning with warm water. Since some foam will appear under the cap, the cap and underlying tip should be pulled apart and rinsed to help prevent build-up of foam and possible blockage.
PROBLEM TO BE SOLVED: To provide a method of manufacturing a Magnoliidae compound.SOLUTION: A Magnoliidae compound is produced by obtaining a part of Magnoliidae plant. The part of Magnoliidae plant is mixed with alcohol and water. The mixture of the part of Magnoliidae plant, alcohol and water is heated and the part of Magnoliidae plant is removed so that a liquid mixture remains. The liquid mixture is dried to form a solid composition. Alcohol and water are added to the solid composition to reconstitute the solid composition into a liquid composition. The liquid composition is heated to form solid matter. The solid matter is dried to obtain purified composition of the Magnoliidae compound. Dosage of the Magnoliidae compound facilitates weight loss, and can be administered in liquid form, sublingually, intravenously, in a pharmaceutically acceptable carrier, in combination with a metabolite antidote, in combination with a nutritional supplement, or in a chewing gum.
In 1995, our study participants enrolled in the Nova Scotia Health Study (NSHS95). At the time of enrollment, epidemiologic data as well as blood samples were obtained. The participants have since been followed prospectively for a variety of health outcomes. We plan to assay stored blood samples collected in 1995 for markers of inflammation and link these results to existing epidemiologic and outcomes data, specifically the 7- year incidence of CAD events.
Bullous pemphigoid (BP) is the most common autoimmune blistering disease, which primarily affects the elderly. However, the relationship between BP and malignancy remains controversial in traditional observational studies. The aim of this study, which included only European populations, was to assess the potential causative link between BP and 13 types of malignant tumors in a two-sample Mendelian randomization (MR) study. BP was not associated with an increased risk of developing 13 types of malignant tumors. This study did not find a causal relationship between BP and malignant tumors. However, further research is warranted to examine the generalizability of this conclusion in non-European populations.
OBJECTIVES: To explore the experiences of socio-culturally diverse community members attempting to manage their chronic pain and enact evidence-based management plans following an index Emergency Department (ED) visit.
METHODS: A convergent parallel mixed-methods design with qualitative interviews and descriptive analysis was undertaken in two public hospitals in a multicultural region in Sydney, Australia. Consecutive adults were recruited from culturally and linguistically diverse (CALD: n = 45) or Australian-born (n = 45) backgrounds, who presented to the ED for a chronic neuromusculoskeletal pain condition. Consenting participants were prescribed an individualised chronic pain management plan following examination by a physiotherapist, who collected standardised measures of pain and health literacy. Six months later, participants underwent a structured phone survey regarding their pain status and whether they had actioned management plans. Participants were invited to participate in a semi-structured interview.
RESULTS: Six-month data were available for 82 of 90 participants who attended the ED and consented to the baseline assessment (40 CALD and 42 Australian-born). Participants were 52% females, predominately middle-aged (mean age 54.7 years), with an overall mean symptom duration of 10 years (SD 9.0). At 6 months, there were nine representations by six CALD participants and 23 by nine Australian-born participants. Overall, 52% reported unchanged pain, 24% were worse and 23% improved, with similar action plan progress for CALD (58%) and Australian-born (53%) participants. Pain features and health literacy were similar, irrespective of progress with pain management plans. From 41 participants who consented to phone interviews, three themes emerged to explain their progress with recommendations: 'illness model', 'urgency' and 'control orientation'.
CONCLUSIONS: Patients presenting to the ED with chronic pain might be more likely to action discharge recommendations if primary care providers identify patient-specific and contextual barriers to implementation.
Drugs that interfere with serotonin reuptake inhibition, including DRIZALMA SPRINKLE, may increase the risk of bleeding events. Concomitant use of aspirin, non-steroidal anti-inflammatory drugs (NSAIDs), warfarin, and other anti-coagulants may add to this risk. Case reports and epidemiological studies (case-control and cohort design) have demonstrated an association between use of drugs that interfere with serotonin reuptake and the occurrence of gastrointestinal bleeding. A post-marketing study showed a higher incidence of postpartum hemorrhage in mothers taking duloxetine. Other bleeding events related to SSRIs and SNRIs use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to life-threatening hemorrhages.

Inform patients about the increased risk of bleeding associated with the concomitant use of DRIZALMA SPRINKLE and NSAIDs, aspirin, or other drugs that affect coagulation [see Drug Interactions (7.1)].
The correlation between obesity, type 2 diabetes mellitus (DM), cardiovascular disease (CVD), and chronic kidney disease (CKD) is an escalating and widely acknowledged epidemic in industrialized nations. Recently, this complex web of interrelated health conditions has been collectively defined as the Cardiovascular-Kidney-Metabolic (CKM) syndrome by the American Heart Association (AHA). The molecular mechanisms underlying CKM disease contain a spectrum of interconnected factors, including hyperglycemia, insulin resistance, heightened activity of the renin-angiotensin-aldosterone system (RAAS), the generation of advanced glycation end-products, oxidative stress, lipotoxicity, endoplasmic reticulum stress, abnormalities in calcium handling, malfunctioning of mitochondria and impaired energy production, as well as persistent chronic inflammation. Addressing their prevention, management, and treatment is of paramount importance to promote better patient health outcomes. The objective of this review is to provide a comprehensive and critical examination of the current state-of-the-art regarding the recently defined CKM syndrome. This includes an exploration of epidemiological evidence establishing connections between cardio-renal-metabolic diseases, an examination of the underlying pathophysiological mechanisms, and a comprehensive overview of existing treatment modalities.
PURPOSE: A magnetic nano-particle and a manufacturing method thereof having curie temperature within biocompatible temperature is provided to minimize side effects due to ferromagnetic characteristics and to be used for effective scanning and separation of biologics. CONSTITUTION: A magnetic nano-particle(10) having curie temperature within a temperature range of -80-41deg. Celsius comprises rare earth metal, divalent metal, and transition metal oxide The rare earth metal is lanthanum series metals. The divalent metal is alkaline earth metal or lead (Pb). The transition metal oxide is manganese oxide. The magnetic nano-particle comprises 0.5-1 molar fraction of the rare earth metal and 0.01-0.5 molar fraction of the divalent metal based on 1 molar fraction of the transition metal. A manufacturing method of the magnetic nano-particle comprises the following steps: forming the magnetic nano-particle by reducing a rare earth metal precursor, transition metal oxide precursor and the divalent metal precursor; and heat-treating the magnetic nano-particle.
How To Take The Pill

The instructions given in the COMBINATION DETAILED PATIENT LABELING AND BRIEF SUMMARY insert are included inside each foil pouch. The instructions include the directions on starting the first pack on Day-One (first choice) of her period and the Sunday start (Sunday after period starts). The patient is advised that, if she used the Sunday start, she should use a back-up method in the first cycle if she has intercourse before she has taken seven pills. The patient is also instructed as to what she should do if she misses a pill or pills. The patient is warned that she may become pregnant if she misses a pill or pills and that she should use a back-up method of birth control in the event she has intercourse any time during the seven day period following the missed pill or pills.

Instructions on how to use the blister for the (28 Tablets) are included in the BRIEF SUMMARY PATIENT PACKAGE INSERT.
Cortical proliferation of the long bones, first observed in dogs, has also been observed in infants during long-term infusions of alprostadil. The cortical proliferation in infants regressed after withdrawal of the drug.

In infants treated with alprostadil injection at the usual doses for 10 hours to 12 days and who died of causes unrelated to ductus structural weakness, tissue sections of the ductus and pulmonary arteries have shown intimal lacerations, a decrease in medial muscularity and disruption of the medial and internal elastic lamina. Localized and aneurysmal dilatations and vessel wall edema also were seen compared to a series of pathological specimens from infants not treated with alprostadil injection. The incidence of such structural alterations has not been defined.

Because alprostadil inhibits platelet aggregation, use alprostadil injection cautiously in neonates with bleeding tendencies.

Alprostadil injection should not be used in neonates with respiratory distress syndrome. A differential diagnosis should be made between respiratory distress syndrome (hyaline membrane disease) and cyanotic heart disease (restricted pulmonary blood flow). If full diagnostic facilities are not immediately available, cyanosis (pO2 less than 40 torr) and restricted pulmonary blood flow apparent on an X-ray are appropriate indicators of congenital heart defects.
The introduction of Doppler ultrasound in obstetrics has allowed evaluating hemodynamic characteristics from the first trimester of pregnancy. For example, Kurjak et al.,in one of the first studies using transvaginal pulsed-wave Doppler ultrasound in early pregnancies, identified the uterine arteries in 100% of the patients. The flow blood of the corpus luteum was identified in 75% patients. The measures obtained by Doppler ultrasonography that may have prognostic value to the evolution of pregnancy include uteroplacental blood flow, also known as trophoblastic flow. Jaffe et al. reported that abnormal Doppler findings were associated with a significantly higher prevalence of complicated pregnancies, among women with abnormal Doppler findings, 43% ended in miscarriage, whereas among women with normal findings only 1.4% of women miscarried.Progesterone plays a crucial role in the maintenance of pregnancy. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator called progesterone induced blocking factor (PIBF), which is anti-abortive in mice . Besides inducing secretary changes in the endometrium and supporting early pregnancy, it modulates the maternal immune response to prevent fetal rejection and relaxes the uterine smooth muscles .CA-125, well-known as a tumor marker for epithelial ovarian cancer , is a high molecular weight glycoprotein that is produced not only by ovarian cancer, but also by nonovarian tumors, normal epithelia of the peritoneum, the endometrium, the fallopian tube, and the ovary. Because CA-125 is also produced by the endometrium, some authors suggest that CA-125 can be used as a marker for endometrial receptivity in patients undergoing IVF . Its role as a predictor for pregnancy outcome is controversial .
The proposal of study approved by the investigators institutional review boards and institution's ethical committee, and all participants will sign a written consent before enter to study. A total of 300 infertile women undergoing sonohysterography will be randomized to intrauterine or intracervical balloon catheter placement. The examination is scheduled in the early follicular phase of menstrual cycle, immediately after cessation of menstrual flow and before day 10. After preparation of patient, a 2 lumen 6-French flexible catheter is introduced into the cervical canal and balloon at the catheter tip is placed in the lower uterine segment or 1 cm into cervical canal and inflated with 1 mL of sterile saline solution. Under sonographic guidance, sterile normal saline solution (10-50 mL) is slowly introduced into the cavity until an adequate distention of the uterine cavity is obtained. Three-dimensional ultrasound scanned volumes are recorded. Patients are asked to assess their level of pain at the time of the balloon inflation and deflation using a 10-point visual analog pain scale. Patients are checked for the sign and symptoms of vasovagal reaction during and 30 minutes after procedure. Outcome measures will be assessed based on the intent-to-treat principle.
PURPOSE: A composition containing pyruvic acid for protecting nerve cells is provided to suppress apoptosis induced by ethanol, and to prevent and treat neurological damage. CONSTITUTION: A composition for protecting nerve cells contains pyruvic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The composition suppresses apoptosis of nerve cells and neurological damage induced by ethanol. The composition prevents or treats FAS(fetal alcohol syndrome)-related brain damage, alcohol-related neurodevelopmental disorders(ARNDs), or sudden infant death syndrome. The composition additionally contains pharmaceutically acceptable carrier. A health functional food for protecting nerve cells contains pyruvic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
FIELD: medicine, anesthesiology, reanimatology. SUBSTANCE: method involves the use of adequate schedules of artificial lung ventilation in combination with additional endobronchial administration of pulmonary surfactant. "Surfactant-BL" is administrated from first hours of respiratory insufficiency development at the dose 700-1000 mg by bolus or microjet route followed by constant dosing in 30-60 min as aerosol for 15-60 h at the dose 30-60 mg/h followed by extubation of patient. Method provides rapid stabilization of patient state and possibility of early softening stringent ventilation indices, significant (up to 15-60 h) decrease of patient under artificial lung ventilation, decrease of total course dose of surfactant and significant increase of viability of patients. Method can be used in treatment of patients with respiratory insufficiency of noncardiogenic nature under critical states. EFFECT: enhanced effectiveness of treatment. 1 tbl, 4 ex
Data for the approximately 15,000 patients who were continuously enrolled during the calendar years 2006 and 2007 in the Generations Plus/ Northern Manhattan Health Network and 226,000 members of a large self insured union trust fund from 2007-2010 will be combined. The data will include age, gender, length of plan enrollment, whether or not the patient is disabled, their diagnoses, and their use of medical and social services.
A conventional rehabilitation program based on structured Cawthorne Cooksey exercises will be applied for 45 minutes with the support of a physiotherapist, once a week for 8 weeks. Exercises will be done twice a day, 10 repetitions. A home exercise program will be created for patients and they will be asked to do 10 repetitions every day, twice a day. The exercise program will be developed individually, progressively, under the guidance of a vestibular therapist.
The first 5 subjects will be reviewed for safety by a Data Safety Monitoring Board (DSMB) at 30 days post-implantation. The 5 subjects will then be followed up to 24 months or until their semen analyses is ≥ 15 million sperm/mL.
Participants will initially receive ibrutinib (420 mg \[milligrams\]/day) for 3 cycles. Venetoclax dose ramp up (from 20 to 400 mg over 5 weeks) will begin at Cycle 4 and the combination of ibrutinib and venetoclax will be given for 12 cycles (each cycle is equivalent to 28 days). Participants who subsequently develop progressive disease may enter to Subsequent Therapy Phase to receive single-agent ibrutinib until disease progression or unacceptable toxicity.
FIELD: medicine, therapy. SUBSTANCE: a biologically active additive - glymuride is given per a capsule in the morning to an empty stomach for 10 d, then - cyclophosphane intravenously for 3 d daily at 10mg/kg patient's body weight. Three weeks later a therapy course should be repeated. During the first year after therapy course conducted it is prescribed cyclophosphane injections at 10 mg/kg patient's body weight once, during the second year cyclophosphane is prescribed at the same dosage but once during 3 mo. Simultaneously, glymuride intake per 1 capsule daily for 10 d should be repeated during 2 years at 5-mo-long interval. The method provides the prevention of progressive inflammatory process. EFFECT: higher efficiency of therapy. 1 ex, 1 tbl
PURPOSE:To obtain a method which intensifies membrane structure and stably preserves liposome in a liquid state without flocculation at the time of preservation by adding diglycerm into a liposome dispersion having a sealing member. CONSTITUTION:The liposome formed by using natural or synthetic lipid is used. A membrane structure intensifying agent and charge imparting agent are added to the constituting components of the liposome membrane in some cases. Either or both of a hydrophilic drug and lipophilic drug are simultaneously used as the sealing member. These materials are prepd. into the liposome by a method, such vortexing method and sonication method. The prepd. liposome liquid is made into the state contg. the unsealed members as they are or the state of removing the unsealed members therefrom, then the diglycerm is added thereto. The amt. of the diglycerm in to be added is specified to 1 to 20 pts.vol. per 100 pts.vol. liposome dispersion. The flocculation is suppressed in this way at the time of preserving the liposome in the liquid state.
"mSYNC" (mHealth SYNdemic-based Consultation \& liaison) is an mHealth HIV prevention intervention to be initially delivered at point-of-care during a visit to the emergency department with continued on demand access to intervention app at home. mSYNC simulates hospital-based consultation and liaison psychology service by intervening on the interrelated health risk behaviors, mental health issues, and structural/treatment needs (e.g., housing, drug use treatment). Capitalizing on the syndemic domino effect, mSYNC aims to promote prevention via entry into at least one of three interacting pathways: decreased HIV/drug use risk behaviors, decreased severity of mental health symptoms, and increased linkage to services. A pilot single-arm feasibility test will be conducted to assess patient-level implementation outcomes of acceptability and appropriateness of the mHealth intervention. Secondarily, change over time will be explored for HIV risk, drug use, mental health symptoms, and linkage to care. The study will take place in two urban emergency departments in Boston, Massachusetts. A sample of N=100 people who use drugs (PWUD) who also belong to other key HIV risk groups (transgender women, men who have sex with men \[MSM\], Black/Latinx/Indigenous people) will be enrolled during a visit to the emergency department. Research staff will pre-screen individuals checked-in and waiting in the emergency department for potential eligibility via information from electronic medical chart (HIV risk or drug use indicator). Staff will then approach potentially eligible patients identified from this pre-screen to describe the study and invite them to be screened for eligibility. Once screened eligible, participants will complete a baseline survey and asked to engage with the mHealth intervention app during their time in the ED (environment- and person-driven intervention dosage). Before discharge, participants will complete a brief feedback survey and asked to use to mHealth at home for at least one time a week for the next 90 days (environment- and person-driven intervention dosage) with the help of automatic notifications personalized to the person. Participants will complete a remote follow-up at 30, 60, and 90 days consisting of a quantitative survey and exit interview (90-day follow-up only).
Approximately 50% of serum cefuroxime is bound to protein. Serum pharmacokinetic parameters for cefuroxime axetil tablets are shown in Table 1.  
Comparative Pharmacokinetic Properties: Cefuroxime axetil for oral suspension was not bioequiv­alent to cefuroxime axetil tablets when tested in healthy adults. The tablet and powder for oral suspension formulations are NOT substitutable on a milligram-per-milligram basis. The area under the curve for the suspension averaged 91% of that for the tablet, and the peak plasma concentration for the suspension averaged 71% of the peak plasma concentration of the tablets. Therefore, the safety and effectiveness of both the tablet and oral suspension formulations had to be established in separate clinical trials.
Women's age will range 25-70 years. Cases will be women diagnosed and surgically intervened of breast cancer, stages I and II.